Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an affirmed reality in the treatment of advanced non-small-cell lung cancer (NSCLC) patients. Atezolizumab, an anti-PD-L1 agent, figures among the drugs that provide previously unenvisaged outcomes in the pretreated set...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchinetti, Francesco, Bordi, Paola, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137949/
https://www.ncbi.nlm.nih.gov/pubmed/30237696
http://dx.doi.org/10.2147/DDDT.S124380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137949/
https://www.ncbi.nlm.nih.gov/pubmed/30237696
http://dx.doi.org/10.2147/DDDT.S124380

Ejemplares similares